UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pharmacology of azoles

Authors
Elizabeth Dodds Ashley, PharmD, MHS, BCPS
John R Perfect, MD
Section Editor
Carol A Kauffman, MD
Deputy Editor
Anna R Thorner, MD

INTRODUCTION

Azole antifungal agents have added greatly to the therapeutic options for treatment of systemic fungal infections. The azoles that are available for systemic use can be classified into two groups: the triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and the imidazoles (ketoconazole).

An overview of the use of azole agents for the treatment of various systemic fungal infections will be reviewed here. Detailed disease-specific treatment recommendations are presented elsewhere. (See "Treatment and prevention of invasive aspergillosis" and "Treatment of chronic pulmonary aspergillosis" and "Treatment of candidemia and invasive candidiasis in adults" and "Treatment of oropharyngeal and esophageal candidiasis" and "Treatment and prevention of Fusarium infection".)

Other systemic antifungal agents, such as amphotericin B and flucytosine, are discussed separately. The use of topical antifungals for onychomycosis and dermatophyte infections is also reviewed elsewhere. (See "Pharmacology of amphotericin B" and "Pharmacology of flucytosine (5-FC)" and "Dermatophyte (tinea) infections" and "Onychomycosis: Epidemiology, clinical features, and diagnosis".)

OVERVIEW OF CLINICAL USES

Members of the triazole family are some of the most widely used antifungal agents [1]. The drugs in this class offer activity against many fungal pathogens without the serious nephrotoxic effects observed with amphotericin B. Newer azole agents have emerged as first-line therapies for several severe fungal diseases, such as invasive aspergillosis, for which voriconazole has become the standard of care.

There are currently five members of the triazole class licensed for use in the United States (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole). It is important for clinicians to appreciate the unique characteristics of each member of this class in order to use azoles appropriately.

                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Sep 15 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Gallagher JC, Dodds Ashley ES, Drew RH, Perfect JR. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 2003; 4:147.
  2. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008; 29:198.
  3. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17:573.
  4. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
  5. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45:1610.
  6. CRESEMBA (isavuconazonium sulfate). Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf (Accessed on March 09, 2015).
  7. Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291.
  8. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol 2007; 2:37.
  9. Diflucan® Package Insert. Roerig, a Division of Pfizer, Inc. New York, NY 2008. http://media.pfizer.com/files/products/uspi_diflucan.pdf (Accessed on December 12, 2008).
  10. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343.
  11. Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988; 157:178.
  12. Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28:363.
  13. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987; 31:6.
  14. Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3:143.
  15. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19:603.
  16. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36:423.
  17. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997; 37:535.
  18. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52:235.
  19. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54:159.
  20. Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993; 7:317.
  21. Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998; 16:33.
  22. Nivoix Y, Levêque D, Herbrecht R, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47:779.
  23. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32:1310.
  24. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37:310.
  25. Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis. Clin Exp Dermatol 1991; 16:374.
  26. Sporanox Package Insert. Janssen Pharmaceuticals. Titusville, NJ 2008. http://www.ortho-mcneil.com/ortho-mcneil/shared/pi/sporanox.pdf (Accessed on December 12, 2008).
  27. Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 2000; 45:371.
  28. VFEND (voriconazole) highlights of prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=618 (Accessed on May 22, 2012).
  29. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004; 64:1997.
  30. Neofytos D, Lombardi LR, Shields RK, et al. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis 2012; 54:913.
  31. Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55:925.
  32. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011; 12:861.
  33. Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis 2014; 209:1941.
  34. Gautier-Veyret E, Fonrose X, Tonini J, et al. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother 2015; 59:2305.
  35. Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 2012; 56:526.
  36. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 2003; 23:1441.
  37. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.
  38. Noxafil (posaconazole). Highlights of prescribing information. https://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf (Accessed on March 18, 2014).
  39. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27:1627.
  40. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57:218.
  41. Krishna G, Ma L, Martinho M, O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012; 56:4196.
  42. Duarte RF, López-Jiménez J, Cornely OA, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014; 58:5758.
  43. Cumpston A, Caddell R, Shillingburg A, et al. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob Agents Chemother 2015; 59:4424.
  44. Durani U, Tosh PK, Barreto JN, et al. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension. Antimicrob Agents Chemother 2015; 59:4914.
  45. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44:211.
  46. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48:3543.
  47. FDA news release. FDA approves new antifungal drug Cresemba. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437106.htm (Accessed on March 09, 2015).
  48. Miceli MH, Kauffman CA. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis 2015; 61:1558.
  49. Ketoconazole product information. Apotex Corp, Toronto, Ontario, Canada, 2004. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3287 (Accessed on December 12, 2008).
  50. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14:13.
  51. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39:1671.
  52. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114:755.
  53. Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991; 35:1765.
  54. Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother 1994; 38:326.
  55. Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997; 41:2714.
  56. Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995; 123:354.
  57. Sharkey PK, Rinaldi MG, Dunn JF, et al. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991; 35:707.
  58. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357:1766.
  59. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28:614.
  60. Boussaud V, Daudet N, Billaud EM, et al. Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus. J Heart Lung Transplant 2008; 27:229.
  61. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29:1240.
  62. Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146:300.
  63. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31.
  64. Ibrahim SF, Singer JP, Arron ST. Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole. Dermatol Surg 2010; 36:1752.
  65. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31:694.
  66. Epaulard O, Villier C, Ravaud P, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis 2013; 57:e182.
  67. Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014; 58:997.
  68. Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009; 9:2845.
  69. Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011; 52:604.
  70. Gerber B, Guggenberger R, Fasler D, et al. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood 2012; 120:2390.
  71. Moon WJ, Scheller EL, Suneja A, et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis 2014; 59:1237.
  72. VFEND (voriconazole) tablets, IV for infusion and oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) – November 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm283035.htm (Accessed on January 21, 2013).
  73. Philips JA, Marty FM, Stone RM, et al. Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007; 9:33.
  74. Alkan Y, Haefeli WE, Burhenne J, et al. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 2004; 39:e49.
  75. Malani AN, Kerr L, Obear J, et al. Alopecia and nail changes associated with voriconazole therapy. Clin Infect Dis 2014; 59:e61.
  76. FDA Antiviral Drugs Advisory Committee. Briefing document for voriconazole (oral and intravenous formulations). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_pfizer.pdf (Accessed on May 09, 2012).
  77. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci 2010; 99:3291.
  78. Astellas Pharma - Isavuconazole. Food and Drug Administration Anti-Infective Drug Advisory Committee. January 22, 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM431846.pdf (Accessed on March 10, 2015).
  79. US Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm (Accessed on July 29, 2013).
  80. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172:599.
  81. Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55:381.
  82. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011; 55:2601.
  83. Koselke E, Kraft S, Smith J, Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother 2012; 67:2957.
  84. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.
  85. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335.
  86. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122.
  87. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.
  88. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801.
  89. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.
  90. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570.
  91. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509.
  92. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532.
  93. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24.
  94. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21:580.
  95. Hostetler JS, Heykants J, Clemons KV, et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993; 37:2224.
  96. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49:928.
  97. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563.
  98. Trifilio SM, Yarnold PR, Scheetz MH, et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009; 53:1793.
  99. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42:1859.
  100. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55:1080.
  101. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61:17.
  102. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2.
  103. Center for Drug Evaluation and Research. Posaconazole (Noxafil, Schering-Plough)-Clinical Pharmacology and Biopharmaceutics Reviews. Application 22-003, 22 December 2005. http://www.fda.gov/cder/foi/nda/2006/022003s000_Noxafil_ClinPharmR.pdf (Accessed on January 30, 2008).
  104. Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011; 55:1308.
  105. Vaes M, Hites M, Cotton F, et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother 2012; 56:6298.
  106. Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69:1162.
  107. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111.
  108. Albengres E, Le Louët H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18:83.
  109. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14:165.
  110. Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004; 43:725.
  111. Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. J Pharm Biomed Anal 1997; 15:1571.
  112. Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68:592.
  113. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003; 42:819.
  114. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994; 18:266.
  115. Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995; 29:994.
  116. Geist MJ, Egerer G, Burhenne J, et al. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 2007; 51:3455.
  117. Spina E, Arena D, Scordo MG, et al. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. Ther Drug Monit 1997; 19:535.
  118. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009; 51:437.
  119. Krishna, G, Moton, A, Ma, L, et al. Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008. http://www.blackwellpublishing.com/eccmid18/abstract.asp?id=69164 (Accessed on July 17, 2008).
  120. Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis 2009; 48:839.
  121. Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56:5503.
  122. Noxafil (posaconazole) oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) – September 2010 and June 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm228417.htm (Accessed on January 21, 2013).
  123. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26:1730.
  124. Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008; 28:719.
  125. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552.